Patrick M. Reagan

16.2k total citations
83 papers, 1.3k citations indexed

About

Patrick M. Reagan is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Patrick M. Reagan has authored 83 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 47 papers in Pathology and Forensic Medicine and 21 papers in Genetics. Recurrent topics in Patrick M. Reagan's work include CAR-T cell therapy research (48 papers), Lymphoma Diagnosis and Treatment (46 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Patrick M. Reagan is often cited by papers focused on CAR-T cell therapy research (48 papers), Lymphoma Diagnosis and Treatment (46 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Patrick M. Reagan collaborates with scholars based in United States, Netherlands and France. Patrick M. Reagan's co-authors include Sattva S. Neelapu, Frederick L. Locke, Jonathan W. Friedberg, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, John M. Rossi and Adrian Bot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Patrick M. Reagan

80 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick M. Reagan United States 19 949 366 330 258 215 83 1.3k
Swati Naik United States 16 561 0.6× 272 0.7× 32 0.1× 238 0.9× 74 0.3× 90 1.0k
Nora Möhn Germany 16 306 0.3× 127 0.3× 224 0.7× 80 0.3× 58 0.3× 49 699
Anna P. Koo United States 15 238 0.3× 272 0.7× 179 0.5× 69 0.3× 46 0.2× 38 935
David Carpentieri United States 19 272 0.3× 116 0.3× 246 0.7× 356 1.4× 22 0.1× 55 1.1k
José Luís Fuster Spain 18 299 0.3× 163 0.4× 36 0.1× 255 1.0× 20 0.1× 60 937
Antonio Giovanni Richetta Italy 19 211 0.2× 467 1.3× 241 0.7× 170 0.7× 31 0.1× 83 985
Lauren M. Lepone United States 15 610 0.6× 344 0.9× 46 0.1× 144 0.6× 26 0.1× 25 869
Annette Wundes United States 15 265 0.3× 161 0.4× 547 1.7× 97 0.4× 41 0.2× 35 813
William H. Stuart United States 12 529 0.6× 282 0.8× 986 3.0× 128 0.5× 45 0.2× 19 1.3k
Simonetta Rizzi Italy 21 359 0.4× 334 0.9× 104 0.3× 362 1.4× 7 0.0× 77 1.4k

Countries citing papers authored by Patrick M. Reagan

Since Specialization
Citations

This map shows the geographic impact of Patrick M. Reagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Reagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Reagan more than expected).

Fields of papers citing papers by Patrick M. Reagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Reagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Reagan. The network helps show where Patrick M. Reagan may publish in the future.

Co-authorship network of co-authors of Patrick M. Reagan

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Reagan. A scholar is included among the top collaborators of Patrick M. Reagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Reagan. Patrick M. Reagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Bei, Patrick M. Reagan, Laurie H. Sehn, et al.. (2025). Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Advances. 9(10). 2489–2499. 3 indexed citations
2.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations
3.
Wang, Yucai, Melissa C. Larson, Anita Kumar, et al.. (2024). Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7006–7006. 1 indexed citations
4.
Friedberg, Jonathan W., Michael T. Brady, Myla Strawderman, et al.. (2024). Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. EClinicalMedicine. 78. 102959–102959. 3 indexed citations
5.
Khurana, Arushi, Raphael Mwangi, Loretta J. Nastoupil, et al.. (2024). Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL. Blood Advances. 8(16). 4414–4422. 4 indexed citations
6.
Strawderman, Myla, Patrick M. Reagan, Paul M. Barr, et al.. (2023). Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population. Clinical Lymphoma Myeloma & Leukemia. 23(9). e260–e267. 1 indexed citations
7.
Roschewski, Mark, Manish R. Patel, Patrick M. Reagan, et al.. (2023). Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical Cancer Research. 29(17). 3301–3312. 13 indexed citations
8.
Zent, Clive S., Andrea Baran, Patrick M. Reagan, et al.. (2023). Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. Blood Advances. 7(11). 2496–2503. 6 indexed citations
9.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372. 1 indexed citations
10.
Janelsins, Michelle C., Mostafa Mohamed, Luke J. Peppone, et al.. (2021). Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy. JNCI Journal of the National Cancer Institute. 114(1). 47–59. 22 indexed citations
11.
Shadman, Mazyar, Marcelo C. Pasquini, Kwang Woo Ahn, et al.. (2021). Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 139(9). 1330–1339. 62 indexed citations
12.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2021). Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances. 5(20). 4149–4155. 45 indexed citations
13.
Williams, AnnaLynn M., Andrea Baran, Patrick M. Reagan, et al.. (2020). Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. Leukemia & lymphoma. 62(3). 598–605. 1 indexed citations
14.
15.
Thomas, Theodore, Suhong Luo, Patrick M. Reagan, et al.. (2019). Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma. Journal of Geriatric Oncology. 11(1). 69–74. 14 indexed citations
16.
Frank, Matthew J., Patrick M. Reagan, Nancy L. Bartlett, et al.. (2018). In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery. 8(10). 1258–1269. 142 indexed citations
17.
Williams, AnnaLynn M., Andrea Baran, Carla Casulo, et al.. (2018). Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 19(1). 41–47. 18 indexed citations
18.
Williams, AnnaLynn M., Andrea Baran, Carla Casulo, et al.. (2017). Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients. Blood. 130. 4050–4050. 1 indexed citations
19.
Reagan, Patrick M.. (2016). Hodgkin Lymphoma in Older Patients. 12(7). 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Swati Naik Breakdown of academic impact, for papers by Nora Möhn Breakdown of academic impact, for papers by Anna P. Koo Breakdown of academic impact, for papers by David Carpentieri Breakdown of academic impact, for papers by José Luís Fuster Breakdown of academic impact, for papers by Antonio Giovanni Richetta Breakdown of academic impact, for papers by Lauren M. Lepone Breakdown of academic impact, for papers by Annette Wundes Breakdown of academic impact, for papers by William H. Stuart Breakdown of academic impact, for papers by Simonetta Rizzi
Rankless by CCL
2026